logo-loader

Arecor advancing today’s therapies to enable healthier lives

Last updated: 02:58 13 Mar 2024 EDT, First published: 04:19 13 Nov 2020 EST

Snapshot

  • Arecor Therapeutics partnership targets $100bn GLP-1 market
  • Arecor to hit stride in 2024, says CEO
  • Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatment
Arecor -

About the company

Arecor Therapeutics PLC is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products.

By applying its innovative proprietary formulation technology platform, Arestat™, the company is developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products.

The Arestat™ platform is supported by an extensive patent portfolio. 

How it is doing

12 Mar 2024

Arecor Therapeutics PLC (AIM:AREC) is teaming up with TRx Biosciences to deliver an oral formulation of a GLP-1 drug similar to the blockbusters used in weight management and diabetes.

In doing so, the pair hope to tap into a market that could be worth $100 billion annually by 2030.

Currently, the main challenge using top-selling products such as Wegovy or Ozempic is they are administered via injection.

While relatively painless, the process is inconvenient. To date, Novo Nordisk (NYSE:NVO)'s Rybelsus is the only GLP-1 receptor agonist available in pill form, exhibiting an oral bioavailability of less than 1%.

29 Feb 2024

Arecor Therapeutics PLC (AIM:AREC) said its subsidiary Tetris Pharma has launched Ogluo, its glucagon-prefilled autoinjector pen, in the Netherlands.

Designed to treat severe hypoglycaemia in individuals with diabetes mellitus, it will be rolled out commercially by Tetris' local partner, Goodlife.

01 Feb 2024

Arecor Therapeutics PLC (AIM:AREC) said it is preparing for another busy year after making significant progress clinically, financially and commercially. Key among those achievements was exiting the period with £6.8 million in the bank - which was more than expected.

In its update, Arecor said it had completed patient enrolment in its AT278 clinical trial, marking a significant step towards the release of key data expected in the first half of 2024.

Insight: Arecor to hit stride in 2024, says CEO

18 Dec 2023

Biotechnology company Arecor Therapeutics PLC (AIM:AREC) expects its Arestat portfolio of pharmaceutical technologies to begin delivering more revenue from 2024 as partnerships with pharma groups hit their stride.  

Arecor chief executive Sarah Howell said she expects the Arestat portfolio to generate more revenue in the form of royalties in 2024 through to 2026, after a milestone payment was triggered last month. 

What management says

13 Mar 2024

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell joined Proactive's Stephen Gunnion with details of a collaboration with TRX Biosciences to develop an oral GLP-1 product for treating type 2 diabetes and obesity.

GLP-1s are therapeutic peptides known for improving blood sugar levels and promoting weight loss. The market for GLP-1 products is expected to reach $100 billion by 2030. Currently, GLP-1 treatment options are predominantly injectable, which limits patient compliance and adoption. Arecor aims to develop an oral GLP-1 with enhanced bioavailability, making it a once-daily pill. This development could significantly increase access to effective treatments for these conditions.

Howell told Proactive that Arecor is well-positioned for this development due to its successful track record with its Arestat technology platform, which enhances the profiles of existing therapeutics. The collaboration aims to overcome challenges faced by the only available oral GLP-1, such as low bioavailability and the need for dosing on an empty stomach, by leveraging Arecor's technology in conjunction with TRX Biosciences' Lipper core technology.

FTSE 100 awaits Rishi Sunak’s Budget today while oil majors rise with higher...

FTSE 100 opened higher helped by a strong start from the oil majors BP and Shell as more brokers predicted crude prices are going to rise higher. Attention will focus on Rishi Sunak’s Budget later today but for now the index is up 38 at 7,515.   Sunak’s announcement comes just after UK...

on 03/23/2022